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Background: Acute myocardial infarction (AMI) is a multifactorial disease with a complex pathogenesis where
lifestyle, individual genetic background and environmental risk factors are involved. Altered inflammatory responses
are implicated in the pathogenesis of atherosclerosis and a premature AMI of parents is associated with an
increased risk of the disease in their offspring (Offs). However, the genetic background of familiarity for AMI is still
largely unknown. To understand which genes may predispose to increased risk of cardiovascular disease gene
polymorphism of immune regulatory genes, and clinical events from the Offs of parents with an early AMI were
investigated. Genetics data from Offs were compared with those obtained from healthy subjects and an
independent cohort of patients with clinical sporadic AMI. Rates of clinical events during a 24 years follow up from
Offs and from an independent Italian population survey were also evaluated.
Results: This study showed that a genetic signature consisting of the concomitant presence of the CC genotype of
VEGF, the A allele of IL-10 and the A allele of IFN-γ was indeed present in the Offs population. In fact, the above
genetic markers were more frequent in unaffected Offs (46.4%) and patients with sporadic AMI (31.8%) than in the
CTR (17.3%) and the differences were highly statistically significant (Offs vs CTR: p = 0.0001, OR = 4.129; AMI vs CTR:
p = 0.0001, OR = 2.224). During the 24-year follow-up, Offs with a positive familiarity in spite of a relatively young
age showed an increased prevalence of diabetes, ischemic heart disease and stroke. These findings reinforce the
notion that subjects with a familial history of AMI are at risk of an accelerated aging of cardiovascular system
resulting in cardiovascular events.
Conclusion: Our data suggest that selected genes with immune regulatory functions are part of the complex
genetic background contributing to familiarity for cardiovascular diseases. This inflammatory genetic profile, along
with classical cardiovascular risk factors, may be used for better defining individual risk of AMI in unaffected
subjects.
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Knowledge of the etiology and pathogenetic mechanisms
of coronary heart disease (CHD) is still limited and in-
complete, and more than 50% of CHD patients do not
have the classical risk factors of hypercholesterolemia,
hypertension, smoking, diabetes, obesity or a sedentary
lifestyle [1]. CHD is the most frequent cause of morbidity* Correspondence: federico.licastro@unibo.it
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reproduction in any medium, provided the orand mortality worldwide [2], and acute myocardial infarc-
tion (AMI) is the main clinical complication of CHD.
AMI is a multifactorial disease with a complex patho-
genesis in which lifestyles, individual genetic backgrounds
and environmental risk factors contribute to the patho-
genetic mechanisms and clinical manifestations: for ex-
ample, abnormal blood lipid and lipoprotein levels [3,4]
along with altered immune factors promote atherogenesis
and lead to AMI [5,6].
It has been suggested that biomarkers of inflammation,
such as increased blood homocysteine [7], C-reactived. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 SNPs list and the number, age and gender
distribution of the CTR, Offs and AMI
Gene polymorphism:
VEGF (rs 699947) SNP at −2578, allele mutation =A
IL-10 (rs 1800896) SNP at −1082, allele mutation =A
IFN-γ (rs 2430561) SNP at +874, allele mutation =A
ACT (rs 1884082) SNP at −51, allele mutation = T
HMG-CR (rs 3761740) SNP at −911, allele mutation =A
IL-1β (rs 16944) SNP at −511, allele mutation = T
N Mean age Gender
CTR 321 72.0 ± 5.1 158 M/163 F
Offs 154 55.8 ± 6.7 80 M/74 F
AMI 267 67.7 ± 12.2 195 M/72 F
Ianni et al. Immunity & Ageing 2012, 9:14 Page 2 of 8
http://www.immunityageing.com/content/9/1/14protein [6], and cytokine levels [8-12], may be new risk
factors for CHD. However, phenotype biomarkers can
vary widely in the same person as a function of time and
may be different among subjects as result of gender,
concomitant diseases, metabolic disorders, dietary intake
and other environmental variables.
Inherited gene variants are less influenced by environ-
ment factors, and may be a better marker of individual
AMI susceptibility, particularly in cases of familial AMI.
A family history of cardiovascular diseases (CVD) and
AMI is frequently encountered in clinical practice, and a
premature heart attack in parents is associated with a
high risk of the disease in their offspring (Offs) [13]. This
initial observation has been confirmed and extended by
other studies showing that parental CVD is a risk factor
for CVD in middle-aged Offs [14]. The relevance of
familial factors to CVD is further supported by the find-
ing that siblings with CVD are at increased risk of future
cardiovascular events (CVE) regardless of the presence of
established risk factors [15]. It has also been shown that
parental longevity relates to carotid atherosclerosis and
aortic arterial stiffness in adult Offs [16]. Data from the
longitudinal Framingham Heart Study confirm that sub-
jects with long-lived parents have a better cardiovascular
risk profile in middle age than those whose parents died
younger [17] and a low cardiovascular risk profile
appears to contribute to the longevity of centenarians
[18]. Furthermore, the Offs of centenarians have a better
cardiovascular risk profile than those of parents not
enjoying a long life [19]. It is interesting to note that
structural vascular changes can be observed in Offs with
a parental history of AMI at a young age, regardless of
the presence of a number of the classical cardiovascular
risk factors [20]. Once again, the Framingham Heart Study
has shown that parental stroke before the age of 65 years
is associated with a 3-fold increase in the risk of stroke in
their Offs, and that parental history can be used as clinical
risk marker of an individual’s propensity to stroke [21].
All of these findings suggest that genetic studies of
Offs may be useful to identifying transmissible genetic
traits in CVD.
We hypothesized that studying unaffected subjects with
positive familiarity for AMI may improve our understand-
ing of the type of genetic background involved in the devel-
opment of atherosclerosis and its complications. Therefore,
we investigated genetic variations represented by single nu-
cleotide polymorphisms (SNPs) in the promoter region of a
number of genes regulating metabolic and immune func-
tions that have previously been found to be associated with
an increased risk of AMI in case/control studies [22].
Genetic data obtained from Offs followed up for
24 years, unrelated patients with clinical AMI, and elderly
controls (CTR) without a history of CVD revealed a
common multi-gene profile in the AMI cases andunaffected Offs with a positive parental history of AMI,
which consisted of SNPs of the VEGF, IL-10, IFN-γ genes.
Offs indeed showed an increased prevalence of CVD. The
pro-inflammatory genetic profile described here may be
useful for predicting individual risk in unaffected subjects.Results
Genotype and allele frequency
Table 1shows the SNP numbers, gene positions and
mutated alleles of the investigated VEGF, ACT, HMG-
CR, IL-1β, IL-10 and IFN-γ genes, together with the
number, mean age and gender of the subjects in the dif-
ferent groups.
The genotype distribution and allele frequency of the
VEGF gene are shown in Table 2. The CC genotype was
more frequent in the Offs than the CTR (63% vs 40.9%,
p = 0.0001), and also more frequent in the AMI group
(65% vs 40.9%, p = 0.0001; OR= 2.689). The percentage
of VEGF C carriers was significantly higher in the AMI
group than in the CTR (95.3% vs 84.5%, p = 0.0001;
OR = 3.735), whereas the percentage of A carriers was
significantly lower in the Offs (37.7%, p = 0.0001) and
the AMI group (35%, p = 0.0001; OR = 0.373) than the
CTR (59.1%). The AA genotype was more frequent in
the CTR than in the AMI group (15.5% vs 4.7%,
p = 0.0001; OR = 0.269).
Table 3 shows the IL-10 genotype distribution and al-
lele frequency in the three groups. The GG genotype
was more frequent in the CTR than in the Offs
(30.5% vs 13%, p = 0.0001) or the AMI group (21.1%,
p = 0.016; OR = 0.609). The A allele was significantly
less frequent in the CTR than in the Offs (69% vs
87.7%, p = 0.0001) or the AMI group (78.9%, p = 0.012;
OR = 1.674). There were also some differences be-
tween the Offs and the AMI group: the GG genotype
was more frequent in the latter (21.1% vs 13%, p= 0.037;
Table 2 Genotype distribution and allele frequency of
VEGF SNP (rs 699947) from Offs, CTR and AMI
VEGF CC (n) % CA (n) % AA (n) % C carriers
(n) %
A carriers
(n) %
Offs (n = 154) (97) 63 (42) 27.3 (15) 9.7 (139) 90.3 (58) 37.7
CTR (n= 291) (119) 40.9 (127) 43.6 (45) 15.5 (246) 84.5 (172) 59.1
AMI (n = 257) (167) 65 (78) 30.4 (12) 4.7 (245) 95.3 (90) 35
Offs vs CTR χ2 = 19.680, p = 0.0001; CC carriers vs non-CC carriers:
χ2 = 19.745, p = 0.0001; A carriers χ2 = 18.545, p = 0.0001.
AMI vs CTR χ2 = 36.906, p = 0.0001; CC carriers vs non-CC carriers:
χ2 = 31.796, p = 0.0001; OR = 2.689 (CI: 1.900-3.806); AA
carriers vs non-AA carriers: χ2 = 16.943, p = 0.0001;
OR= 0.269 (CI: 0.139-0.521); C carriers χ2 = 17.063,
p = 0.0001; OR= 3.735 (CI: 1.929-7.232); A carriers
χ2 = 31.733, p = 0.0001; OR = 0.373 (CI: 0.264-0.527).
Offs vs AMI χ2 = 4.141, p = 0.126.
Table 4 SNP IFN-γ (rs 2430561) genotype distribution
and allele frequency from Offs, CTR and AMI.
IFN-γ TT (n) % TA (n) % AA (n) % T carr (n)
%
A carr (n)
%
Offs (n = 153) (24) 15.7 (88) 57.5 (41) 26.8 (112) 73.2 (129) 84.3
CTR (n= 268) (82) 30.6 (111) 41.4 (75) 28 (193) 72.0 (186) 69.4
AMI (n = 240) (58) 24.2 (96) 40 (86) 35.8 (154) 64.2 (182) 75.8
Offs vs CTR χ2 = 13.990, p = 0.001; TT carriers vs non-TT carriers:
χ2 = 11.070, p = 0.001; A carriers χ2 = 11.495, p = 0.001
AMI vs CTR χ2 = 4.423, p = 0.110
Offs vs AMI χ2 = 11.704, p = 0.003; TT carriers vs non-TT carriers:
χ2 = 4.380, p = 0.036; OR = 1.761 (CI: 1.032-3.002); A carriers
χ2 = 4.070, p = 0.044; OR = 0.584 (CI: 0.345-0.988).
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among the Offs (87.7% vs 78.9%, p = 0.02), in whom the
frequency of the AA genotype was also higher (35.1% vs
AMI =25.7%, p = 0.043).
Table 4 shows IFN-γ genotype and allele distribution.
The TT genotype was more frequent in the CTR than in
the Offs (30.6% vs 15.7%, p = 0.001), whereas the per-
centage of A carriers was higher among the Offs than
the CTR (84.3% vs 69.4%, p = 0.001). No difference in
the distribution of the IFN-γ polymorphism between the
AMI group and the CTR was detected, but the fre-
quency of the TT genotype was slightly higher in the AMI
group than in Offs (24.2% vs 15.7%, p = 0.036; OR= 1.761)
and the A allele was less frequent in the AMI group than
Offs (75.8% vs 84.3%, p = 0.044; OR=0.584).
The SNPs in the promoter region of the ACT, HMG-
CR and IL-1β genes were also investigated, but noTable 3 IL-10 SNP (rs 1800896) genotype distribution and
allele frequency from Offs, CTR and AMI
IL-10 GG (n) % GA (n) % AA (n) % G carriers
(n) %
A carriers
(n) %
Offs (n = 154) (20) 13 (80) 51.9 (54) 35.1 (101) 65.6 (135) 87.7
CTR (n= 239) (73) 30.5 (88) 36.8 (78) 32.6 (161) 67.4 (165) 69
AMI (n = 265) (56) 21.1 (141) 53.2 (68) 25.7 (197) 74.3 (209) 78.9
Offs vs CTR χ2 = 17.378, p = 0.0001; GG carriers vs non-GG carriers:
χ2 = 15.981, p = 0.0001; A carriers χ2 = 17.984. p = 0.0001
AMI vs CTR χ2 = 13.887, p = 0.001; GG carriers vs non-GG carriers:
χ2 = 5.845, p = 0.016; OR = 0.609 (CI: 0.407-0.912); A carriers
χ2 = 6.344, p = 0.012; OR = 1.674 (CI: 1.179-2.504)
Offs vs AMI χ2 = 6.550, p = 0.038; GG carriers vs non-GG carriers:
χ2 = 4.352, p = 0.037; OR = 1.795 (CI: 1.031-3.126); AA
carriers vs non-AA carriers: χ2 = 4.077, p = 0.043; OR= 0.642
(CI: 0.418-0.989); A carriers χ2 = 5.126, p = 0.024; OR = 0.525
(CI: 0.299-0.923).statistically significant difference in allele and genotype
frequencies between the groups was found (data not
shown).
Association between the triple genotype and
cardiovascular risk
The concomitant presence of the CC genotype of VEGF,
the A allele of IL-10 and the A allele of IFN-γ was also
determined and resulted to be associated with an
increased risk of AMI, as shown in Table 5. This “triple
genotype” was more frequent in the Offs (46.4%) and the
AMI (31.8%) than in CTR (17.3%), and the differences were
highly statistically significant (Offs vs CTR: p = 0.0001,
OR = 4.129; AMI vs CTR: p = 0.0001, OR = 2.224).
Body mass index (BMI) and blood lipid profile
Data regarding BMI and serum lipid profile from Offs,
CTR and IMA have been reported in Table 6. BMI
values of Offs and IMA were slightly increased (27 ± 4)
as compared with ideal age matched reference value.
Moreover, BMI from our CTR group was higher than
Offs and IMA, however this difference may be mainly
ascribed to the older age of CTR.
Lipid profile from the Offs population was substan-
tially in the normal range for their age cohort. Once
again CTR population showed slightly increased bloodTable 5 Concomitant presence of the triple genotype in
Offs, CTR and AMI
Triple
genotype
Carriers (n) % Non-carriers (n) %
Offs (n = 153) (71) 46.4 (82) 53.6
CTR (n= 301) (52) 17.3 (248) 82.7
AMI (n = 239) (76) 31.8 (163) 68.2
Offs vs CTR χ2 = 43.295, p = 0.0001
AMI vs CTR χ2 = 15.372, p = 0.0001; OR= 2.224 (CI: 1.484-3.332)
Table 6 BMI values and blood lipid profiles from Offs,
CTR and AMI.
N° Mean St.
Deviation
Post hoc
statistics
BMI Offs 154 27 4 Offs vs CTR*
CTR 320 29 4 Offs vs IMA**
IMA 265 27 4 CTR vs IMA*
Total cholesterol Offs 148 216 43 Offs vs CTR*
CTR 265 241 39 Offs vs IMA*
IMA 209 199 39 CTR vs IMA*
HDL Offs 148 60 17 Offs vs CTR**
CTR 265 60 15 Offs vs IMA*
IMA 209 47 16 CTR vs IMA*
LDL Offs 137 132 36 Offs vs CTR*
CTR 241 157 34 Offs vs IMA**
IMA 189 127 38 CTR vs IMA*
Triglycerides Offs 148 111 64 Offs vs CTR**
CTR 265 122 70 Offs vs IMA*
IMA 209 140 117 CTR vs IMA*
VLDL Offs 148 22 13 Offs vs CTR**
CTR 265 24 14 Offs vs IMA*
IMA 209 28 23 CTR vs IMA*
*p = 0.0001.
**p≥ 0.05; not statistically significant.
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expected according their age range.
As shown in Table 7, no statistical difference for BMI,
total cholesterol, HDL, LDL, triglycerides and VDL values
between Offs carriers and non carriers for the triple geno-
type was detected.Table 7 BMI and blood lipid parameters in Offs carriers
or non carriers of the triple genotype.
Triple
genotype
Offs
N° Mean St.
Deviation
statistics
BMI Carriers 71 26 4 not significant
Not carriers 82 27 4
Total cholesterol Carriers 66 215 35 not significant
Not carriers 81 215 47
HDL Carriers 66 60 14 not significant
Not carriers 81 60 18
LDL Carriers 64 134 31 not significant
Not carriers 72 130 38
Triglycerides Carriers 66 100 53 not significant
Not carriers 81 120 74
VLDL Carriers 66 20 11 not significant
Not carriers 81 24 15Prevalence of cardiovascular events (CVE) after 24 years
of follow up
The prevalence rates of a history of ischemic heart dis-
ease (AMI or angina pectoris), stroke, ischemic heart
disease plus stroke, hypertension, diabetes and smoking
in 154 Offs at the beginning (age 23–35 years; Table 8,
panel A) and at the end of the follow up period (age 50–
60 years; Table 8, panel B) were compared with those of
gender and age matched subjects from the MONICA-
Brianza population. No difference in the event rates was
present between the two populations at the beginning of
the follow up period. On the contrary, at the end of the
follow up the prevalence of ischemic heart disease
among the male Offs was three times higher, that of
stroke was eight times higher, that of stroke and ische-
mic heart disease was three times higher, and that of dia-
betes was twice as high. However, there was no
increased prevalence of CVE among female Offs during
the same period.Discussion
The multiple pathogenetic pathways leading to AMI in-
clude genetic heterogeneity or multiple genetic traits
associated with the disease. Recent genome-wide associ-
ation (GWA) studies have contributed substantially to
the discovery of new SNPs associated with CHD and
AMI [23], but their clinical relevance is still unclear be-
cause a single gene variant can make a limited contribu-
tion to the total genetic load of AMI, and both common
and rare gene polymorphisms may differentially affect
susceptibility to the disease. These factors may also par-
tially explain the contradictory results of genetic associ-
ation studies using the candidate gene approach in AMI
case/control studies [24-26].
It is important to know that subjects with an affected
parent have a two-fold greater risk of CHD than those
without a family history [13-15]. Genetic studies of the
children of parents with CVD have shown that genetic
variations in the promoter region of the APOA1 gene
are associated with differences in serum ApoA1 and
HDL levels in healthy subjects, and that this effect is influ-
enced by gender and a family history of AMI [27]. A par-
ental history of hypertension is a risk factor for high blood
pressure among Offs, whose blood pressure is partially
affected by variations (deletions/insertions) in the angio-
tensin converting enzyme [28]. Hyper-homocysteinemia is
frequent in homozygotes for the C677T polymorphism of
the MTHFR gene and associated with an increased risk of
CHD in children with a positive family history [29]. It has
also been found that the same SNP is associated with con-
genital atrial septal defects, and that these heart alterations
are more frequent in the children from mothers carrying
the MTHFR TT genotype [30].
Table 8 Cardiovascular events in Controls and Offs during a 24 years follow up.
panel A
Male Female
MONICA-Brianza Offs P MONICA-Brianza Offs P
Age 25-35 (1984) † Age 25-35 (1984) †
N % N % N % N %
Subjects 727 - 84 - - 768 - 70 - -
Ischemic heart disease* 3 0.4 1 1.2 { 2 0.3 0 0 {
Stroke 1 0.1 0 0 { 0 0 0 0 {
Heart disease/stroke 4 0.6 1 1.2 { 2 0.3 0 0 {
Hypertension 72 9.9 4 4.8 { 63 8.2 2 2.9 {
Diabetes mellitus 2 0.3 0 0 { 2 0.3 1 1.4 {
Smoking 292 40.2 29 34.5 { 240 31.3 27 38.6 {
panel B
MONICA-Brianza Offs P MONICA-Brianza Offs P
Age 50-60 (2008) † Age 50-60 (2008) †
N % N % N % N %
Subjects 970 - 84 - - 967 - 70 - -
Ischemic heart disease* 38 3.9 9 10.7 0.01 16 1.7 1 1.4 {
Stroke 6 0.6 4 4.8 0.01 3 0.3 0 0 {
Heart disease/stroke 44 4.5 13 15.5 0.0001 19 2 1 1.4 {
Hypertension 268 27.6 29 34.5 { 350 36.2 20 28.6 {
Diabetes mellitus 39 4 8 9.5 0.05 30 3.1 5 7.1 {
Smoking 354 36.5 17 20.2 0.003 145 15 13 18.6 {
*Myocardial infarction or angina pectoris.
† Fisher’s exact test.
{ Not significant (p ≥0.05).
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defined genetic background greatly influence the early
clinical manifestation of AMI and CVD. Therefore, we
investigated SNPs in genes with a regulatory effect on
inflammatory responses as possible genetic markers of
an increased risk of CVD in children of parents with a
positive history of AMI. It is interesting that 45% of the
Offs in our investigation had a father who suffered an
AMI before he reached the age of 56 years.
We chose elderly CTR from a longitudinal population
study because they did not have a history of CVD, and did
not experience an AMI or have any other CVD before
and during the five years of follow-up. A second control
group of comparable age from the WHO-MONICA-
Brianza study to compare the CVE prevalence during the
24 years follow-up of our Offs was also used. The control
disease consisted of patients with clinical sporadic AMI.
SNPs in the VEGF, IL-10 and IFN-γ genes were differ-
ently distributed in Offs and CTR, and it is interesting
to note that the genetic make-up of the Offs overlapped
that of the unrelated population of patients with a clin-
ical diagnosis of sporadic AMI (control disease).It has been suggested that the CC genotype of the
VEGF gene, together with two other SNPs in the pro-
moter region of this gene, increases VEGF gene expres-
sion in human myoblasts [31] and the production of the
cognate protein in human peripheral blood lymphocytes
activated by lipopolisaccaride [32]. Subjects with the
VEGF CC genotype may produce increased levels of
VEGF protein which, by deregulating angiogenesis, may
lead to an increased risk of CVE.
The published data regarding the functional relevance
of IL-10 SNPs are conflicting. An initial study found that
the IL-10 A allele is associated with a two-fold increase
in transcriptional activity in B cell lines [33], but it has
been subsequently reported that the A allele is asso-
ciated with a reduction in the IL-10 secretion of acti-
vated peripheral blood lymphocytes [34-36]. These data
support the hypothesis that the suppression of inflam-
mation may be impaired in carriers of the −1082 A allele
in the IL-10 gene. These findings suggest that impaired
regulation of inflammatory responses in Offs with one
or two copies of the IL-10 A allele may increase the risk
of CVE.
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production of the cognate protein and resistance to tu-
berculosis infection [37]. Our findings showing an
increased frequency of the +874 A allele in Offs are in
accordance with another study reporting that patients
with the +874 AA genotype and idiopathic dilated car-
diomyopathy showed a worse prognosis and an adverse
outcome [38]. Furthermore, patients with dilated cardio-
myopathy showed an impaired activation of CD4T cells
by IFN-γ ascribed to a decreased production of this
cytokine [39]. These findings suggest that a decreased
release of IFN-γ may negatively affect the coordination
of immune responses in vessel walls, accelerate athero-
genesis, and increase the risk of CVE in Offs with the
IFN-γ A allele.
The concomitant presence of the CC genotype of
the VEGF gene, the A allele of the IL-10 gene, and
the A allele of the IFN-γ gene was more frequent in
our AMI group, and significantly increased the risk
of the disease. It is interesting to note that this triple
genotype profile was found in 46% of Offs and led
to a presumptive high risk of CVE (OR = 4.129). This
observation supports the notion that Offs with a
positive parental history are at high risk of CVE and
the pro-inflammatory genetic signature may be part
of the complex genetic background influencing AMI
risk.
The increased risk of CVE predicted by genetic signa-
ture was partially confirmed by the 24-year follow-up,
which clearly revealed a significant increase in CVE in
Offs. Furthermore, gender and age are also strong risk
factors, as CVE increased prevalence was only observed
in older male Offs (Table 8). The type of relationship be-
tween the presence of the triple genotype and CVE
manifestation could not be assessed, since the limited
number of Offs positive for CVE. Further follow up of
these subjects may clarify this topic.
BMI from Offs was slightly increased when compared
with the ideal age value and CTR selected for this inves-
tigation showed an increased BMI as expected since
their advanced age. Cholesterol blood profile data from
Offs group were in the normal range for their age co-
hort. Among Offs only 33 subjects used for limited time
periods statins and the number of statins users was fur-
ther reduced when it was stratified between triple geno-
type carriers and non carriers. Therefore, statins use
showed very limited influence upon the lipid profile
data from Offs population. Furthermore, since the
presence of the triple genotype/allele signature did
not affect BMI or the blood levels of total cholesterol,
HDL, LDL or triglycerides, we suggest that it might
affect the incidence of CVE by mechanisms that are
partially independent of those affected by the classic
risk factors of CVD.Conclusions
The concomitant presence of the CC genotype of
VEGF, the A allele of IL-10 and the A allele of IFN-γ
resulted to be associated with an increased risk of
AMI and was more frequent among Offs with a posi-
tive parental history of AMI. Therefore, genes with an
immune regulatory function appear to be associated
in the pathogenesis of AMI. Inflammatory genes, gen-
der and age influence an accelerated aging of cardio-
vascular system and selected genes with immune
regulatory functions are part of the complex genetic
background contributing to familiarity for cardiovas-
cular diseases.Methods
Subjects and patients
The study involved 154 Offs from Northern Italy, each
of whom had one parent who had experienced an AMI
before the age of 65 years. An evaluation was made of
the classic AMI risk factors (metabolic parameters,
smoking, diabetes, obesity, a sedentary lifestyle) together
with ECG records, anthropometric indices, arterial pres-
sure and medical history. The Offs were re-screened
after a follow-up of 24 years in order to assess any
changes in behavioral and biological risk factors and col-
lect blood samples for laboratory and genetic evaluation.
The CVD risk factors and drug treatments recorded at
baseline and 24 years later were compared with those of
the age-matched population of the WHO-MONICA
Project, which were collected in Brianza, Northern Italy,
during independent surveys carried out in 1984, 1991
and 2004 [40]. A further group of 269 consecutive
patients with a clinical diagnosis of AMI based on elec-
trocardiographic changes and standard laboratory find-
ings, and confirmed by echocardiography and coronary
angiography [22], who were admitted to the Cardiology
Unit of Ferrara University Hospital during 2006–2007,
was investigated. The healthy CTR were 315 subjects
without a family history of CVD participating in the
“Conselice study of brain aging” conducted in Northern
Italy in 1999–2005 [41], none of whom showed any signs
of CVD or inflammatory diseases before or during the
study.
The plasma cholesterol and lipid profiles of the Offs,
AMI patients and CTR were determined on the basis of
standard laboratory procedures.
The research protocol was approved by our Institutional
Review Boards, and all of the participants gave their writ-
ten informed consent.DNA extraction
Genomic DNA was extracted from peripheral blood leu-
kocytes as described elsewhere [42].
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The presence of SNPs in the promoter regions of the
VEGF (−2578 C/A), ACT (−51 G/T) and HMG-CR
genes (−911 C/A) was assessed by means of polymerase
chain reaction (PCR)-based methods as previously
described [43-45]. SNPs in the IL-1β (−511 C/T), IL-10
(−1082 G/A) and IFN-γ genes (+874 T/A) were detected
by real-time PCR. The SNP-specific primers and probes
were designed using the TaqMan genotyping assay (ABI,
Foster City, CA) in a 25 μl total volume of BIORAD
CFX 96 in accordance with the manufacturer’s instruc-
tions [22].
Statistical analysis
The different genotypes were statistically analyzed using
contingency tables and the chi-square (χ2) test, and the
odds ratios (OR) and their statistical significance were
also calculated. The mean values of the various quantita-
tive variables were compared by means of one-way ana-
lysis of variance (ANOVA) followed by appropriate post-
hoc comparisons and Bonferroni’s correction. Statistical
tests were two-sided, and significance was set at
p< 0.05.
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